Please check your internet connection and try again.
# Flupentixol and Melitracen
## Overview
Flupentixol/melitracen is a fixed-dose combination psychotropic agent. Flupentixol is a thioxanthene antipsychotic with anxiolytic and antidepressant properties at low doses. Melitracen is a tricyclic antidepressant (TCA) with energizing properties. The combination is primarily intended for the treatment of mild-to-moderate anxiety, depression, and apathy.
## Primary Indications
* Psychogenic depression
* Depressive neurosis
* Masked depression
* Anxiety and apathy in psychosomatic conditions
* Neurasthenia
## Adult Dosing
* **Initial Dose:** 1 tablet (0.5 mg flupentixol / 10 mg melitracen) twice daily (morning and noon).
* **Maintenance Dose:** 1 tablet daily (morning).
* **Maximum Dose:** 2 tablets twice daily (total 4 tablets/day) for severe cases.
* *Note: Dosing varies by regional regulatory approval; consult local prescribing information.*
## Pediatric Dosing
* **Safety and Efficacy:** Not established. Use is generally not recommended in children or adolescents due to the presence of a TCA (melitracen) and potential for serious adverse events.
## Dose Adjustments
* **Elderly:** Start with 1 tablet in the morning. Use with extreme caution due to TCA-related anticholinergic risks (urinary retention, cognitive impairment, orthostasis).
* **Hepatic/Renal Impairment:** No standard adjustment guidelines exist; use with caution or avoid due to reliance on hepatic metabolism.
## Contraindications
* Hypersensitivity to flupentixol or melitracen.
* Recent myocardial infarction.
* Conduction defects (heart block, bundle branch block).
* Acute alcohol, barbiturate, or opioid poisoning.
* Blood dyscrasias.
* Narrow-angle glaucoma.
* Pyloric stenosis or paralytic ileus.
* Concomitant use of MAO inhibitors (must stop MAOI at least 14 days prior).
## Adverse Effects
* **Common:** Dry mouth, insomnia, restlessness, dizziness, tremor, tachycardia.
* **Serious:** Extrapyramidal symptoms (EPS), tardive dyskinesia, QT interval prolongation, seizure threshold reduction, urinary retention.
* **TCA-specific:** Orthostatic hypotension, blurred vision, constipation, weight gain.
## Key Drug Interactions
* **MAO Inhibitors:** Risk of hypertensive crisis.
* **CNS Depressants:** Enhanced sedation with alcohol, benzodiazepines, or opioids.
* **Antihypertensives:** Potential for increased hypotension.
* **QT Prolonging Agents:** Increased risk of ventricular arrhythmias when combined with other drugs prolonging the QT interval.
* **Anticholinergics:** Synergistic risk of urinary retention and constipation.
## Monitoring
* **Cardiovascular:** Baseline and periodic ECG, especially in patients with pre-existing cardiac risks.
* **Neurological:** Monitor for EPS or signs of tardive dyskinesia during long-term therapy.
* **Metabolic:** Weight and glycemic status monitoring if used long-term.
## Clinical Pearls
* **Timing:** Administer doses in the morning and at noon. Avoid late afternoon or evening dosing to minimize the risk of insomnia caused by the stimulating effect of melitracen.
* **Withdrawal:** Avoid abrupt cessation; taper slowly to prevent withdrawal symptoms related to the TCA component.
* **Safety:** The effect of the drug generally takes 2–3 days to appear. Do not exceed the maximum daily dose.
***
**Disclaimer:** This information is for educational purposes only. Prescribing guidelines, approved indications, and dosing protocols may vary by country and region. Always consult the latest local Summary of Product Characteristics (SmPC) or official prescribing information before initiating therapy.
